Articles On Neuren Pharmaceuticals (ASX:NEU)

The ASX200 closed flat despite futures having tipped a moderate green day on market as investors endeavoured to digest the Australian CPI report.  Core inflation has declined by 0.1 per cent from 4.2 to 4.1 per cent – and while that’s he...

Lithium miners surge NextDC also jumps on strong H1, but Flight Centre tumbles Aussie inflation lowest in two years   The ASX 200 closed modestly lower on Wednesday with, with gains in Tech offset by losses in Comm Services and Staples se...

The ASX200 has been trading quite flat. The IT sector has surged, up more than 2 per cent, while telecommunications is struggling, shedding about a per cent. The Australian Bureau of Statistics (ABS) reported a 3.4 per cent rise in in...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down 0.1% to 7,654.3 points. Four ASX shares that are falling more than most today are listed...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are crashing deep into the red today. At one stage today, the ASX 200 pharmaceuticals stock was down 15% to $18.16. Neuren's shares have recovered a touch since then but remain down by 12%. Why...

  Neuren’s Daybue sales meet target Proteomics granted patent in Europe Nyrada’s brain injury drug shows efficacy in animal testing   Neuren’s Daybue sales meet target, crushing short seller’s claims Neuren Pharma (ASX:NEU) says Q4 2023 s...

Neuren has reported over US$87M in sales of DAYBUE in Q4 of 2023 The drug is sold by NASDAQ-listed Acadia in the US to treat a condition called Retts Earlier this month, short sellers claimed Acadia was lying to the market about the...

One in eight people in the world have some form of mental disorder TrivarX’s AI technology diagnoses mental health via sleep monitoring Stockhead reached out to TrivarX’s COO, Kai Sun   Mental health has always been a big global issue, bu...

If you want to receive the next Insurance Australia Group Ltd (ASX: IAG) dividend, then you will have to act fast. That's because the insurance giant's shares are going ex-dividend on Wednesday. When a share trades ex-dividend, it means th...

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

It turned out to be a shaky, but still positive, start to the trading week for the S&P/ASX 200 Index (ASX: XJO) and most shares this Monday. By the close of trading tod...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

By Greg Peel Resourceful The ASX200 shot up 76 points from the open on Friday on a combination of renewed positive sentiment over the week and a 0.5% gain on Wall Street. It then dipped and finally steadied through the afternoon to close up...

On Friday, the S&P/ASX 200 Index (ASX: XJO) ended the week with a solid gain. The benchmark index rose 0.7% to 7,658.3 points. Will the market be able to build on this on Monday? Here are five things to watch: ASX 200 expected to edge...

It's funny to call an ASX stock that's rocketed 217% in the past year a "bargain". But that's precisely the situation we have with Neuren Pharmaceuticals Ltd (ASX: NEU), according to the experts at Blackwattle. Let's check out their ration...

ASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to a softening US dollar and general commodity weirdness Small caps led by NKOTB, Australian Wealth Advisors Group on a solid debut   Materi...

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX sh...

We had a team meeting this morning. We were discussing how to make sure our readers and members were best equipped to use our advice. Spoiler: some of the people who get grumpy with our advice are those who, ahem, don't actually follow it....

Neuren Pharmaceuticals (ASX:NEU) shares are tanking on news its US partner allegedly mischaracterised the safety of a drug for children The findings come from a short-selling firm That firm, Culper Research, reports the drug hospital...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are ending the week deep in the red. The ASX 200 healthcare share was down 13% to $20.04 before being paused from trade. What's going on with this ASX 200 healthcare share? Investors have been h...

The S&P/ASX 200 Index (ASX: XJO) has just given ASX investors a not-so-merry start to December today, closing the trading week with a mild loss....

The S&P/ASX 200 Index (ASX: XJO) was on form in November and charged higher. Over the period, the benchmark index rose 4.5% to finish the period at 7,087.3 points. While most ASX 200 shares climbed with the market, some stood out wit...

ASX health stocks flat in past five days in line with broader markets  Avita lowers full year 2023 guidance after slower progress in its customer’s VAC processes EBOS decides against acquisition of animal care business, reportedly Greencro...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a positive start to the week. In afternoon trade, the ASX 200 pharmaceutical stock is up almost 2% to $14.93. Why is this ASX 200 stock rising? The catalyst for the rise in Neuren's s...

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a subdued note. The benchmark index fell 0.1% to 7,049.4 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 200 expe...

ASX health stocks rise in past five days and outpace broader markets for second week All study visits complete in Neuren’s Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid Syndrome Ramsay Health Care after revealing that it has reach...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

At the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our ESG-focused portfolio. These stocks, many of which have global reach, have the potential to generate attractive returns while shaping a bet...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Neuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 for Phelan-McDermid syndrome has completed all study visits.

ASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US FDA approves weight loss drug Clinical stage immuno-oncology small cap Immutep gains 160%  Morgans healthcare and life sciences expert Iain...

ASX erased yesterday’s gains on Fed chair Powell’s hawkish tilt The RBA has revised its inflation target upward Job seekers’ services stock APM was worst large cap after issuing a warning   The ASX erased yesterday’s gains, down by -0.5%...

ASX closed modestly higher as stocks were up across the board Xero slumped 13pc, despite delivering strong half-year results Optus CEO can’t explain in layman terms the root cause of yesterday’s outage   The ASX rose by 0.2% on Thursday,...

It was a great start to the trading week this Monday for the S&P/ASX 200 Index (ASX: XJO). After a great week last week, the ASX 200 kept the train rolling dow...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

We’re coming to you from Perth Town Hall, where the Young Investor Carnival has been held today. It’s an event hosted by the Young Investor Circle, to help educate new investors. You can see interviews with some of the panellists in o...

The S&P/ASX 200 Index (ASX: XJO)'s so-far lucrative month of November continued this Friday. After banking gains on Wednesday and yesterday, the ASX 200 finishe...

ASX lifted 1pc on Friday, up 3pc for the week Neuren, Block Inc, Lendlease, and media stocks were the best gainers FTX founder Sam Bankman-Fried found guilty on all charges   The ASX tracked Wall Street to close 1% higher today. For the w...

Neuren Pharmaceuticals (ASX: NEU) is expecting to receive increasing royalty payments from its US partner Acadia Pharmaceuticals, with sales of the recently launched DAYBUE treatment continuing to surge. The Australian pharmaceutical compan...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a very positive note. At the time of writing, the benchmark index is up 1.1% to 6,977.1 points. Four ASX shares that are rising more than most today...

Welcome to our market update, coming to you from the Young Investor Carnival at the Perth Townhall today. The event – held by the organisation, Young Investor Circle, is all about educating those new to investment through panel discussio...

  Neurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS With no approved therapy for PANDAS/PANS Neurotech is pursing orphan drug designation for NTI164 Results of Neurotech’s phase 1/2 trial inves...

Neuren’s blockbuster drug DAYBUE generates big sales in Q3 Argenica jumps 40pc after releasing preclinical results from Alzheimer’s trial Integral Diagnostics crashes 30pc after conceding more inflationary pressures ahead   Neuren’s DAYBU...

In some much-needed relief, the S&P/ASX 200 Index (ASX: XJO) has given investors a big day of relief. By the end of this Tuesday's session, the ASX 200 had shrugge...

The S&P/ASX 200 Index (ASX: XJO) has once again started the trading week off on the wrong side of the bed. After giving investors relief from the sell-offs we have...

ASX-listed Impedimed Limited Pharmaceuticals (ASX:IDP), Avita Medical (ASX:AVH), and Neuren Pharmaceutical (ASX:NEU) lead in share price increase for 2023 while Lumos Diagnostics (ASX: LDX) tops third-quarter rankings.

The S&P/ASX 200 Index (ASX: XJO) had gotten through a bumpy, but overall positive day of trading this Wednesday. After spending time in both positive and negative territory...